MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Reclassification of breast cancer: Towards improved diagnosis and outcome
Reclassification of breast cancer: Towards improved diagnosis and outcome
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reclassification of breast cancer: Towards improved diagnosis and outcome
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Reclassification of breast cancer: Towards improved diagnosis and outcome
Reclassification of breast cancer: Towards improved diagnosis and outcome

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Reclassification of breast cancer: Towards improved diagnosis and outcome
Reclassification of breast cancer: Towards improved diagnosis and outcome
Journal Article

Reclassification of breast cancer: Towards improved diagnosis and outcome

2019
Request Book From Autostore and Choose the Collection Method
Overview
The subtyping of breast cancer based on features of tumour biology such as hormonal receptor and HER2 status has led to increasingly patient-specific treatment and thus improved outcomes. However, such subgroups may not be sufficiently informed to best predict outcome and/or treatment response. The incorporation of multi-modal data may identify unexpected and actionable subgroups to enhance disease understanding and improve outcomes. This retrospective cross-sectional study used the cancer registry Surveillance, Epidemiology and End Results (SEER), which represents 28% of the U.S. population. We included adult female patients diagnosed with breast cancer in 2010. Latent class analysis (LCA), a data-driven technique, was used to identify clinically homogeneous subgroups (\"endophenotypes\") of breast cancer from receptor status (hormonal receptor and HER2), clinical, and demographic data and each subgroup was explored using Bayesian networks. Included were 44,346 patients, 1257 (3%) of whom had distant organ metastases at diagnosis. Four endophenotypes were identified with LCA: 1) \"Favourable biology\" had entirely local disease with favourable biology, 2) \"HGHR-\" had the highest incidence of HR- receptor status and highest grade but few metastases and relatively good outcomes, 3) \"HR+ bone\" had isolated bone metastases and uniform receptor status (HR+/HER2-), and 4) \"Distant organ spread\" had high metastatic burden and poor survival. Bayesian networks revealed clinically intuitive interactions between patient and disease features. We have identified four distinct subgroups of breast cancer using LCA, including one unexpected group with good outcomes despite having the highest average histologic grade and rate of HR- tumours. Deeper understanding of subgroup characteristics can allow us to 1) identify actionable group properties relating to disease biology and patient features and 2) develop group-specific diagnostics and treatments.